openPR Logo
Press release

Gastroparesis Market is Expected to Showcase a Significant Growth at a CAGR of X% by 2034, as per DelveInsight

04-26-2024 02:44 AM CET | Health & Medicine

Press release from: ABNewswire

Gastroparesis Market is Expected to Showcase a Significant

DelveInsight's "Gastroparesis Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Gastroparesis, historical and forecasted epidemiology as well as the Gastroparesis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Key Takeaways from the Gastroparesis Market Report

* The total Gastroparesis Market Size was found to be around USD 200 million in 2023 in the US, which is further expected to increase by 2034 with the approval of several new therapies in the market.
* In 2023, the Gastroparesis market size of the United Kingdom accounted for approximately USD 10 million, which is expected to increase during the forecast period.
* As per DelveInsight analysis, the Gastroparesis Market is anticipated to witness growth at a considerable CAGR.
* The leading Gastroparesis Companies working in the market include Vanda Pharmaceuticals, Processa Pharmaceuticals, Neurogastrx, CinDome Pharma, and others.
* Promising Gastroparesis Therapies in the various stages of development include Velusetrag, tadalafil, PCS12852, Naronapride, and others.
* April 2024:- CinDome Pharma Inc.- A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Diabetic Gastroparesis. The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastroparesis in adult patients.

Discover which therapies are expected to grab the Gastroparesis Market Share @ Gastroparesis Market Outlook [https://www.delveinsight.com/sample-request/gastroparesis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Gastroparesis Overview

Gastroparesis is a condition that affects the stomach muscles, causing them to function improperly or not at all. This condition slows down or stops the movement of food from the stomach to the small intestine. Symptoms can include nausea, vomiting, abdominal pain, feeling full quickly when eating, and bloating. It's often caused by damage to the vagus nerve, which controls the muscles of the stomach. Diabetes, certain medications, and surgery are common causes of gastroparesis. Treatment may include dietary changes, medications to stimulate stomach emptying, and in severe cases, surgery.

Gastroparesis Epidemiology Insights

The epidemiology section of Gastroparesis offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

Download the report to understand which factors are driving Gastroparesis Epidemiology trends @ Gastroparesis Epidemiological Insights [https://www.delveinsight.com/sample-request/gastroparesis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Gastroparesis Marketed Therapies

* GIMOTI (metoclopramide) Nasal Spray: Evoke Pharma

Gastroparesis Emerging Therapies

* VLY-686 (tradipitant): Vanda Pharmaceuticals
* PCS12852: Processa Pharmaceuticals

Gastroparesis Drugs Market

The Gastroparesis Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Gastroparesis signaling in Gastroparesis are likely to uncover new therapeutic targets and further expand treatment options for patients.

Gastroparesis Treatment Market Landscape

The Gastroparesis treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Gastroparesis has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

To learn more about Gastroparesis treatment guidelines, visit @ Gastroparesis Treatment Market Landscape [https://www.delveinsight.com/sample-request/gastroparesis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Gastroparesis Market Outlook

The report's outlook on the Gastroparesis market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Gastroparesis therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Gastroparesis drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Gastroparesis market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

Gastroparesis Drugs Uptake

The drug chapter of the Gastroparesis report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Gastroparesis.

Major Gastroparesis Companies

Several Gastroparesis Companies working in the market include Vanda Pharmaceuticals, Processa Pharmaceuticals, Neurogastrx, CinDome Pharma, and others.

Learn more about the FDA-approved drugs for Gastroparesis @ Drugs for Gastroparesis Treatment [https://www.delveinsight.com/sample-request/gastroparesis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Gastroparesis Market Report

* Coverage- 7MM
* Gastroparesis Companies- Vanda Pharmaceuticals, Processa Pharmaceuticals, Neurogastrx, CinDome Pharma, and others.
* Gastroparesis Therapies- Velusetrag, tadalafil, PCS12852, Naronapride, and others.
* Gastroparesis Market Dynamics: Gastroparesis Market Drivers and Barriers
* Gastroparesis Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Gastroparesis Drugs in development @ Gastroparesis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/gastroparesis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

1. Key Insights

2. Report Introduction

3. Executive Summary of Gastroparesis

4. Gastroparesis Market Overview at a Glance

5. Key Events

6. Epidemiology and Market Forecast Methodology

7. Disease Background and Overview

8. Epidemiology and Patient Population

9. Patient Journey

10. Marketed Therapies

11. Emerging Therapies

12. Gastroparesis: Six Major Market Analysis

13. Unmet Needs

14. SWOT Analysis

15. KOL Views

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=gastroparesis-market-is-expected-to-showcase-a-significant-growth-at-a-cagr-of-x-by-2034-as-per-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Gastroparesis Market is Expected to Showcase a Significant Growth at a CAGR of X% by 2034, as per DelveInsight here

News-ID: 3476969 • Views:

More Releases from ABNewswire

Integris Roofing Expands Services to Houston, Offering Top-Quality Roof Repair Solutions
Integris Roofing Expands Services to Houston, Offering Top-Quality Roof Repair S …
Integris Roofing, renowned for its commitment to excellence and unparalleled service in the roofing industry, has recently made a significant stride by expanding its services to Houston. This expansion marks a pivotal moment for both Integris Roofing and the residents of Houston, as it brings forth a new era of top-quality roof repair solutions to the area. Houston, a bustling metropolis known for its dynamic energy and diverse architectural landscape, presents
Schneider Electric invests Rs 100 cr in new cooling factory in Bengaluru
Schneider Electric invests Rs 100 cr in new cooling factory in Bengaluru
Schneider Electric, a global player in energy management and automation, has invested Rs 100 crore in a new cooling factory in Bengaluru, officially launched on Thursday. The company has also earmarked an investment of Rs 3,200 crore in India by 2026 to expand its presence across the country. The cooling factory in Bengaluru, spanning about 6.5 acres, will focus on developing "innovative" cooling solutions to meet the growing exponential demand for
Schneider Electric to invest 3,200 crore in India to grow footprint, enhance tech capabilities by 2026
Schneider Electric to invest 3,200 crore in India to grow footprint, enhance tec …
In a significant move that underscores its commitment to India's growing industrial and technological sector, Schneider Electric India plans to invest 3,200 crore to enhance its industrial footprint across the country by 2026. The expansion will include an addition of 12,00,000 square feet of space spread over nine states, including Gujarat, Telangana, Karnataka, West Bengal, Odisha, Tamil Nadu, Maharashtra, Himachal Pradesh, and Uttarakhand, Deepak Sharma, President-Greater India Zone and MD
Schneider Electric Confirms Early Stage Talks to Acquire Bentley Systems
Schneider Electric Confirms Early Stage Talks to Acquire Bentley Systems
A visualization of the ITER tokamak fusion reactor created with Bentley's Lumen RT. Schneider Electric's interest in further digitization of the design and construction process may align with Bentley Systems' strong background in building information modeling and digital twins. Schneider Electric SE, the French technology, electrical automation and energy management company, has said it is in talks for a potential deal to purchase a controlling stake in Bentley Systems, the Exton,

All 5 Releases


More Releases for Gastroparesis

Gastroparesis Drugs Market Analysis by 2020-2025
Scope of the Report: The worldwide market for Gastroparesis Drugsis expected to grow at a CAGR of roughly x% over the next five years, will reach x million US$ in 2024, from x million US$ in 2019, according to a new Global Info Researchstudy. The report presents the market outlook for the Indian Phospho Gypsum product from the year 2019 to the year 2025. The report provides a definition of the product.
Gastroparesis Drugs Market - Use of Gastroparesis Drugs Is Highest In North Amer …
The Gastroparesis Drugs Market is projected to reach $ 6,448.6 billion, an average annual rate of 4.7% from 2017 to 2023. Gastric paralysis affects the normal spontaneous movement of the gastrointestinal muscles and interferes with normal digestion, causing problems related to nausea, vomiting and blood sugar levels and nutrition. Gastroparesis can be caused by diabetes or after surgery. Recently, advanced drugs such as metoclopramide, erythromycin, and anti-vomiting have been developed to
Diabetic Gastroparesis-Pipeline Review H1 2017
ReportsWeb.com has announced the addition of the “Diabetic Gastroparesis-Pipeline Review H1 2017” this report provides an overview of the Diabetic Gastroparesis-Pipeline landscape.  Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Gastroparesis - Pipeline Review, H1 2017, provides an overview of the Diabetic Gastroparesis (Gastrointestinal) pipeline landscape. Gastroparesis is a long-term complication of diabetes that involves the stomach and affects digestion. Prolonged high blood sugar levels can damage nerves in many parts
Diabetic Gastroparesis - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Diabetic Gastroparesis - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Gastroparesis - Pipeline Review, H2 2017, provides an overview of the Diabetic Gastroparesis (Gastrointestinal) pipeline landscape. Gastroparesis is a long-term complication of diabetes that involves the stomach and affects digestion. Prolonged high blood sugar levels
Gastroparesis Global Clinical Trials Review, H2, 2017
GlobalData's clinical trial report, Gastroparesis Global Clinical Trials Review, H2, 2017" provides an overview of Gastroparesis clinical trials scenario. This report provides top line data relating to the clinical trials on Gastroparesis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status
Diabetic Gastroparesis - Pipeline Market Research Report, 2017
Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Diabetic Gastroparesis - Pipeline Insight, 2017”. This report provides comprehensive insights about pipeline drugs across this Diabetic Gastroparesis. The key objective of the report is to establish the understanding for all the pipeline drugs that are undergoing research across Diabetic Gastroparesis. Request For Sample Report@ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1214082 This report provides information on the therapeutic development for